|
1
|
Harris AL: Hypoxia - a key regulatory
factor in tumour growth. Nat Rev Cancer. 2:38–47. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Semenza GL: HIF-1 and tumor progression:
pathophysiology and therapeutics. Trends Mol Med. 8:S62–S67. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Bruick RK and McKnight SL: A conserved
family of prolyl-4-hydroxylases that modify HIF. Science.
294:1337–1340. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Epstein AC, Gleadle JM, McNeill LA, et al:
C. elegans EGL-9 and mammalian homologs define a family of
dioxygenases that regulate HIF by prolyl hydroxylation. Cell.
107:43–54. 2001. View Article : Google Scholar
|
|
5
|
Ivan M, Kondo K, Yang H, et al: HIFalpha
targeted for VHL-mediated destruction by proline hydroxylation:
implications for O2 sensing. Science. 292:464–468. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Jaakkola P, Mole DR, Tian YM, et al:
Targeting of HIF-alpha to the von Hippel-Lindau ubiquitylation
complex by O2-regulated prolyl hydroxylation. Science.
292:468–472. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Jeong JW, Bae MK, Ahn MY, et al:
Regulation and destabilization of HIF-1alpha by ARD1-mediated
acetylation. Cell. 111:709–720. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Lu X and Kang Y: Hypoxia and
hypoxia-inducible factors: master regulators of metastasis. Clin
Cancer Res. 16:5928–5935. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Mole DR, Blancher C, Copley RR, et al:
Genome-wide association of hypoxia-inducible factor (HIF)-1alpha
and HIF-2alpha DNA binding with expression profiling of
hypoxia-inducible transcripts. J Biol Chem. 284:16767–16775. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Xia X, Lemieux ME, Li W, et al:
Integrative analysis of HIF binding and transactivation reveals its
role in maintaining histone methylation homeostasis. Proc Natl Acad
Sci USA. 106:4260–4265. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Semenza GL: Targeting HIF-1 for cancer
therapy. Nat Rev Cancer. 3:721–732. 2003. View Article : Google Scholar
|
|
12
|
Giaccia A, Siim BG and Johnson RS: HIF-1
as a target for drug development. Nat Rev Drug Discov. 2:803–811.
2003. View
Article : Google Scholar : PubMed/NCBI
|
|
13
|
Belozerov VE and Van Meir EG: Hypoxia
inducible factor-1: a novel target for cancer therapy. Anticancer
Drugs. 16:901–909. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Salminen A, Lehtonen M, Paimela T and
Kaarniranta K: Celastrol: molecular targets of thunder god vine.
Biochem Biophys Res Commun. 394:439–442. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Hervouet E, Cizkova A, Demont J, et al:
HIF and reactive oxygen species regulate oxidative phosphorylation
in cancer. Carcinogenesis. 29:1528–1537. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Jin X, Jin HR, Lee D, Lee JH, Kim SK and
Lee JJ: A quassinoid 6alpha-tigloyloxychaparrinone inhibits
hypoxia-inducible factor-1 pathway by inhibition of eukaryotic
translation initiation factor 4E phosphorylation. Eur J Pharmacol.
592:41–47. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Jin HR, Jin SZ, Cai XF, et al:
Cryptopleurine targets NF-κB pathway, leading to inhibition of gene
products associated with cell survival, proliferation, invasion,
and angiogenesis. PLoS One. 7:e403552012.PubMed/NCBI
|
|
18
|
Hagen T, Taylor CT, Lam F and Moncada S:
Redistribution of intracellular oxygen in hypoxia by nitric oxide:
effect on HIF1alpha. Science. 302:1975–1978. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Choi YK, Kim CK, Lee H, et al: Carbon
monoxide promotes VEGF expression by increasing HIF-1alpha protein
level via two distinct mechanisms, translational activation and
stabilization of HIF-1alpha protein. J Biol Chem. 285:32116–32125.
2010. View Article : Google Scholar
|
|
20
|
Lee JH, Koo TH, Yoon H, et al: Inhibition
of NF-kappa B activation through targeting I kappa B kinase by
celastrol, a quinone methide triterpenoid. Biochem Pharmacol.
72:1311–1321. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Pang X, Yi Z, Zhang J, et al: Celastrol
suppresses angiogenesis-mediated tumor growth through inhibition of
AKT/mammalian target of rapamycin pathway. Cancer Res.
70:1951–1959. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Huang Y, Zhou Y, Fan Y and Zhou D:
Celastrol inhibits the growth of human glioma xenografts in nude
mice through suppressing VEGFR expression. Cancer Lett.
264:101–106. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Yang H, Chen D, Cui QC, Yuan X and Dou QP:
Celastrol, a triterpene extracted from the Chinese “thunder of god
vine,” is a potent proteasome inhibitor and suppresses human
prostate cancer growth in nude mice. Cancer Res. 66:4758–4765.
2006.
|
|
24
|
Laughner E, Taghavi P, Chiles K, Mahon PC
and Semenza GL: HER2 (neu) signaling increases the rate of
hypoxia-inducible factor 1alpha (HIF-1alpha) synthesis: novel
mechanism for HIF-1-mediated vascular endothelial growth factor
expression. Mol Cell Biol. 21:3995–4004. 2001. View Article : Google Scholar
|
|
25
|
Thomas GV, Tran C, Mellinghoff IK, et al:
Hypoxia-inducible factor determines sensitivity to inhibitors of
mTOR in kidney cancer. Nat Med. 12:122–127. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Hart S, Novotny-Diermayr V, Goh KC, et al:
VS-5584, a novel and highly selective PI3K/mTOR kinase inhibitor
for the treatment of cancer. Mol Cancer Ther. 12:151–161. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Lachance PE, Miron M, Raught B, Sonenberg
N and Lasko P: Phosphorylation of eukaryotic translation initiation
factor 4E is critical for growth. Mol Cell Biol. 22:1656–1663.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Fukuda R, Hirota K, Fan F, Jung YD, Ellis
LM and Semenza GL: Insulin-like growth factor 1 induces
hypoxia-inducible factor 1-mediated vascular endothelial growth
factor expression, which is dependent on MAP kinase and
phosphatidylinositol 3-kinase signaling in colon cancer cells. J
Biol Chem. 277:38205–38211. 2002. View Article : Google Scholar
|
|
29
|
Ueda T, Watanabe-Fukunaga R, Fukuyama H,
Nagata S and Fukunaga R: Mnk2 and Mnk1 are essential for
constitutive and inducible phosphorylation of eukaryotic initiation
factor 4E but not for cell growth or development. Mol Cell Biol.
24:6539–6549. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Liu LP, Ho RL, Chen GG and Lai PB:
Sorafenib inhibits hypoxia-inducible factor-1alpha synthesis:
implications for antiangiogenic activity in hepatocellular
carcinoma. Clin Cancer Res. 18:5662–5671. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Bjornsti MA and Houghton PJ: Lost in
translation: dysregulation of cap-dependent translation and cancer.
Cancer Cell. 5:519–523. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
De Benedetti A and Graff JR: eIF-4E
expression and its role in malignancies and metastases. Oncogene.
23:3189–3199. 2004.PubMed/NCBI
|
|
33
|
Wang X, Yue P, Chan CB, et al: Inhibition
of mammalian target of rapamycin induces phosphatidylinositol
3-kinase-dependent and Mnk-mediated eukaryotic translation
initiation factor 4E phosphorylation. Mol Cell Biol. 27:7405–7413.
2007. View Article : Google Scholar
|
|
34
|
Wendel HG, De Stanchina E, Fridman JS, et
al: Survival signalling by Akt and eIF4E in oncogenesis and cancer
therapy. Nature. 428:332–337. 2004. View Article : Google Scholar : PubMed/NCBI
|
